John O’Brien, President and CEO of the National Pharmaceutical Council, weighs in on ICER’s latest update that we are calling a “faux update”; The American Enterprise Institute has released its perspective on last year’s Inf…
Bill Smith, Director of the Life Sciences Initiative at the Pioneer Institute, dives into the so-called update to ICER’s value assessment framework; Congresswoman Cathy McMorris Rodgers explained earlier this year why she wa…
Avalere releases a study focused on ICER assessments and whether or not they take into account the patient experience when creating their reports; Wayne Winegarden, a Senior Fellow with the Pacific Research Institute explain…
Donna Cryer, CEO of the Global Liver Institute, previews liver disease patient advocates’ testimonies ahead of an ICER meeting on two new treatments; the House Health, Employment, Labor and Pensions Subcommittee holds a hear…